Toward new sources of insulin-producing cells for diabetes

سال انتشار: 1397
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 430

نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد

این مقاله در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

ITERMED01_323

تاریخ نمایه سازی: 7 مرداد 1398

چکیده مقاله:

According to the international diabetes federation (IDF) report, every 7 seconds a person dies from diabetes in the world. There is a critical need to develop therapeutic strategies aiming for restoration of functional β-cell mass in both types of diabetes. Bone marrow mesenchymal stromal cells (MSCs) are an attractive tool in regenerative medicine due to the lack of human leucocyte antigen (HLA) class II as well as anti-inflammatory and anti-apoptotic properties. There are evidence that co-transplantation of pancreatic islets with MSCs, prolongs islet survival after transplantation which shows the potential of MSCs for beta cell repair in the pancreas for diabetes therapy. The cell nucleus is able to initiate reprogramming via certain chemical compound, cell fusion, transcription-factor transduction or nuclear transfer. In this study, Human puromycin+eGFP+ MSCs were cultured with INS-1E cells as a rat beta cell line and treated with all-trans retinoic acid to induce beta cell differentiation by chemical compound as well as phytohemagglutinin (PHA-P) and polyethylene glycol (PEG) to induce fusion. Beta-MSC Fused cells and human MSCs were selected by puromycin treatment. Our previous results show fused cells had higher insulin content and improved insulin secretion compared to the mixed control. Interestingly, our new results show elevated human NKX2.2, NEUROD1, PDX1, MAFA, and insulin mRNA compared to mixed control or fusion protocol separately. In conclusion, we introduced a virus-free and rapid combined fusion and chemical compound protocol to generate β-MSCs which express human beta cell markers. This strategy will provide a new source of insulin-producing cells that can be used for treatment of diabetes.

نویسندگان

Zahra Azizi

Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran

Amir Norouzy

Institute of Industrial and Environmental Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran